ARTICLES BY ERIC LANGER

• Cell And Gene Therapy Bioprocessing: Hiring And Capacity Crunch On The Horizon

  5/21/2020

  With a very healthy R&D pipeline of cell and gene therapies, we can expect multiple blockbuster products and various “orphan” niche products to be launched annually in coming years. As a result, the industry is heading for a capacity crunch.

• A Biopharma Year In Review — And A Look Ahead To 2020

  12/16/2019

  The industry has shown surprising resilience and consistency, emerging relatively unscathed from the recession at the beginning of the past decade. Capacity and expansion were relatively unaffected and continue to draw investors seeking healthy returns and a recession-resistant risk profile.

• Bioprocessing Trends To Watch In 2018

  12/6/2017

  The current situation in biopharma is exciting, with new technologies, biosimilars, cellular and gene therapies, and opportunities in emerging markets.  And these innovative platforms are going to continue to need improved manufacturing technologies in the future.

• Biosimilars Paving The Way For Cost-Effective Bioprocessing

  8/23/2017

  As biosimilars finally move into mainstream commerce in the world’s major (bio)pharmaceutical markets, they are bringing with them some side benefits. Sponsors frequently focus resources on production technologies that generate higher productivity and yields. Some of these cutting-edge technologies are applicable to mainstream pipeline biologics, so future biopharmaceuticals will benefit from this push for efficiency.

• 4 Key Trends In Biopharmaceutical Manufacturing In 2016

  3/16/2016

  One of the most important trends to emerge from preliminary results of this year’s survey is the increased attention paid to continuous bioprocessing. Integrated, broad up- and downstream technologies remain to be developed and commercialized. Despite this lack of viable options, there is a groundswell of enthusiasm for the concept.

• Regulatory Concerns For Facilities Of The Future: Does Flexibility Come With A Cost?

  12/22/2015

  Trends in biomanufacturing follow a slow cycle, partly due to the regulated nature of the industry and the substantial costs and risks that introducing a change in the process can bring. But that ignores the benefits that changes in bioprocessing over the past 10 years have brought, from better expression systems, to new modular and flexible facilities, sensors, and control systems for downstream operations.